A cross-sectional study assessing the relationship between disease and burden associated with ATTR-CM found that both patients ... Federation on Transthyretin Amyloid Cardiomyopathy The World ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

Tafamidis not only improves survival but also mitigates cardiac structural changes and functional declines, underscoring its ...

The study investigated the efficacy and safety of acoramidis given twice daily compared with placebo, in subjects with ATTR-CM. The study met its primary clinical endpoints by significantly ...

for acoramidis for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule, orally administered ...